Answers are grounded in this paper and cite their sources.
Antibody-drug conjugates (ADCs) have established roles in the treatment of several hematologic malignancies, although clinical outcomes vary substantially across constructs and treatment settings. Target biology influences ADC delivery, while intracellular trafficking, linker processing, and the properties of released species shape intracellular drug exposure, bystander activity, and cellular injury. This Review integrates these mechanisms with clinical evidence stratified using a descriptive Levels of Evidence (LoE I-V) framework, while identifying preclinical or translational findings and abstract-only reporting separately. Same-target ADC comparisons can inform linker-payload redesign, although existing clinical evidence rarely isolates the contribution of individual design features. We also examine resistance across the ADC therapeutic cascade, mechanistically distinct sources of toxicity, and integration with chimeric antigen receptor (CAR) T-cell therapy and T-cell engagers. Candidate biomarkers encompass target expression and heterogeneity, intracellular processing and catabolite transport, drug efflux, and payload sensitivity, with differing levels of clinical support. Linker-payload pharmacology complements target-based classification but is insufficient on its own to guide ADC selection or treatment sequencing. Prospective target-anchored studies incorporating pharmacokinetic and biomarker assessments are needed to determine whether specific ADC design modifications improve the clinical benefit-risk balance and whether candidate biomarkers can guide patient selection.
No takes yet. Share an insight, caveat, or question.
Zheng et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: